TScan Therapeutics, Inc. (TCRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TScan Therapeutics, Inc. on June 22, 2026. The filing discloses positive initial data from Cohort C of the ongoing ALLOHA Phase 1 clinical study evaluating the company's lead product candidate, TSC-101. The study focuses on patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation (HCT) and utilizes a commercial-ready manufacturing process.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical trial progress and regulatory disclosures.
Material Changes and Clinical Highlights
The primary material event is the release of clinical data for Cohort C of the ALLOHA study. Key highlights include:
- Enrollment and Manufacturing: 19 patients were enrolled with a ~90% manufacturing success rate (17/19) using the commercial-ready process.
- Transplant and Infusion: 14 of 19 patients proceeded to transplant and received their first infusion of TSC-101. Of these, 10 received a planned second infusion, and 1 received a third infusion.
- Non-Transplant: 3 patients did not proceed to transplant due to clinical reasons.
- Chimerism Outcomes: Using a high-sensitivity NGS assay (Alloheme) with a 0.2% cut-off, 11 of 14 patients achieved complete donor chimerism within approximately 3 weeks of the first infusion. Two of the remaining three patients are approaching complete donor chimerism.
- Long-term Data: One patient with TP53 mutated AML remained in complete donor chimerism 6 months post-HCT.
- Safety Profile: TSC-101 infusions were generally well-tolerated. Safety was consistent with Cohort A, and observed adverse events were consistent with standard post-HCT adverse events.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the Company's strategy, operations, and future expectations. Management emphasizes that these statements involve substantial risks and uncertainties, including factors discussed in the "Risk Factors" section of the Company's quarterly and annual reports. The Company explicitly disclaims any obligation to update these forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and company presentation (Exhibit 99.2) for detailed statistical tables and patient demographics.
- Review the Company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K does not contain financial figures.
- Confirm the specific definitions of "complete donor chimerism" and the assay methodology used in the Alloheme test.
- Monitor upcoming regulatory filings for any updates on the manufacturing process scale-up or subsequent clinical trial phases.